bluuebunny/crossref_metadata_2025_split huggingface dataset:
Bidirectional Links of Daily Sleep Quality and Duration With Pain and Self-rated Health in Older Adults’ Daily Lives
Authors: Lücke Anna J , Wrzus Cornelia , Gerstorf Denis , Kunzmann Ute , Katzorreck Martin , Hoppmann Christiane , Schilling Oliver K 
Published: September 2022

Abstract

Background
Sleep and health perceptions, such as self-ratings of pain and health are closely linked. However, the temporal ordering of such associations is not well understood, and it remains unclear whether sleep quality and sleep duration show similar or differential associations with health perceptions.

Methods
We used ecological momentary assessment data from 123 young-old (66–69 years, 47% women) and 47 old-old adults (84–90 years, 60% women). Across 7 consecutive days, participants reported their sleep quality and sleep duration each morning and rated their momentary pain and health 6 times per day. We applied dynamic structural equation models to examine bidirectional links of morning reports of sleep quality and duration with daily levels of self-rated pain and health.

Results
In line with the hypotheses, results showed that when participants reported better sleep quality than what is typical for them, they reported less pain and better self-rated health on the day that followed. Longer sleep duration was not linked with subsequent pain or self-rated health. On days when people rated their health as better than usual, they reported better sleep quality but not longer sleep duration the following night. These associations were not moderated by age, gender, or chronic pain.

Conclusion
Findings suggest that in old age, sleep quality is more relevant for health perceptions than sleep duration. Associations between sleep quality and self-rated health seem to be bidirectional; daily pain was linked to prior but not subsequent sleep quality.
Wavelet Characterizations of Operator-Valued Hardy Spaces
Authors: Hong Guixiang , Wang Wenhua , Wu Xinfeng 
Published: September 2022

Abstract
Let $\mathcal {M}$ be a von Neumann algebra equipped with a normal semifinite faithful trace $\tau $, and $H_{p}(\mathbb {R},\,\mathcal {M}) (1\leq p&lt;\infty )$ be the operator-valued Hardy spaces introduced by Tao Mei. In this paper, we characterize the operator-valued column Hardy space $H^c_{p}(\mathbb {R},\,\mathcal {M}) (1\leq p&lt;\infty )$ by using several square functions involving wavelets, which corresponds to Meyer’s wavelet characterizations of the classical Hardy space when $p=1$.
Habits, Rule-of-thumb Consumption and Useful Public Consumption in Sub-Sahara Africa: Theory and New Evidence
Authors: Nana Francois John 
Published: September 2022

AbstractAggregate consumption behaviour of private agents is central in the mediation and effectiveness of macroeconomic policies, and it is therefore of first-order importance. In this paper, I derive and estimate a structural consumption model for a panel of 34 sub-Sahara African (SSA) countries from 1960 to 2018 to provide new evidence on three important aggregate consumption behaviours—habit formation, rule-of-thumb consumption behaviour and the complementarity of government consumption in private utility. The following key findings emerge. (1) There is evidence of habit formation in aggregate consumption. (2) Approximately 38% of consumers follow the rule-of-thumb of consuming their current income suggesting a deviation from the permanent income hypothesis in SSA. However, this rule-of-thumb consumption behaviour in the data is driven by the period before the mobile banking/money era that emerged post-2000s. (3) Public consumption complements private consumption in an Edgeworth–Pareto sense. This suggests that expansionary fiscal policies involving increases in government consumption can be an effective vehicle in stimulating aggregate demand via a positive marginal utility channel. These findings are robust to demographic factors and stable under different model assumptions.
Locally advanced breast cancer arising in the axilla
Authors: Sapon-Cousineau Sasha , Moldoveanu Dan , Charpentier Danielle , Gagnon Alain , Patocskai Érica 
Published: September 2022

Abstract
Locally advanced breast cancer arising from ectopic axillary breast tissue is an unusual presentation of this malignancy. The work-up and treatment approach pose some unique challenges. We present the case of a 37-year-old female presenting with a left axillary lesion with skin involvement. Radiological studies and biopsy demonstrated an underlying axillary mass compatible with a triple-positive invasive ductal carcinoma of the breast. Following neoadjuvant therapy, the patient underwent nipple-sparing mastectomy with wide local excision of the involved axillary skin and axillary lymph node dissection. Ectopic locally advanced breast cancer can be treated similarly to its orthotopic counterpart, favoring a neoadjuvant therapy approach followed by surgical excision. Special considerations include the local anatomy of the tumor, the extent of surgery and reconstructive options.
Establishment of Review Criteria Coordinating With the Automated Digital Cell Morphology Identification System in a Specialized Women’s and Children’s Hospital
Authors: Wang Yuefang , Ye Lei , Chen Lan , Chen Qi , Zhang Xia , Dai Qingkai , Peng Luyun , Lai Chunqi , Zhang Ge 
Published: September 2022

Abstract

Objective
We aimed to establish appropriate review criteria for blood cell analysis in a specialized women’s and children’s hospital. Also, the CellaVision DI-60, was developed as one of the automated digital cell morphology analyzer, we evaluated if it was shown to be most effective under the certain review criteria.

Methods
A total of 2890 blood samples were detected to optimize the previously established review criteria for women and children with the Sysmex XE-2100. A total of 623 samples were used to validate the criteria.

Results
The microscopic-review rate based on the initial review criteria was 51.0%. After optimization, it was reduced to 17.3% and the false-negative rate was 3.85%. There was &gt; 80% consistency between manual review results and CellaVision DI-60 preclassification when samples triggered the platelet- or red cell-related rules. The sensitivity for abnormalities (immature granulocytes, nucleated red blood cells) of reclassification was 90% to 100% and the false-negative rate was &lt; 5%. However, direct microscopic review was required when the “Blasts/AbnLympho?” and “Atypical Lympho?” flags were triggered.

Conclusion
Specialized review criteria are needed for women and children. An automated morphology identification system might help to improve the review criteria.
M1.2 Human pythiosis
Authors: Plongla Rongpong , Chindamporn Ariya 
Published: September 2022

Abstract

Meet the expert session, September 22, 2022, 8:00 AM - 9:00 AM
Human pythiosis is a rare, life-threatening infection, which is generally caused by Pythium insidiosum, a fungal-like oomycete. Four forms of human pythiosis are described: 1) vascular pythiosis affecting the patient's arteries causing arteritis, thrombosis, and gangrene; 2) ocular pythiosis, mainly causing infections of the cornea; 3) skin and soft tissue infections (cutaneous and subcutaneous pythiosis); and 4) disseminated pythiosis. Vascular pythiosis is associated with high morbidity and has a mortality rate of 10%-40%, which attributes to difficulties in diagnosis of the infection and the lack of effective standard treatment. Rice farmers and patients with thalassemia are at risk for vascular infection. Early diagnosis of Pythium infection requires a high index of clinical suspicion and is essential for good treatment results. Microscopic morphology of Pythium spp. resembles other non-septate hyphae, such as agents of mucormycosis. Definite laboratory diagnosis includes tissue cultivation with zoospore induction, polymerase chain reaction (PCR), and detection of Pythium antibodies. Radical surgery together with immunotherapy, and anti-fungal agents (e.g., terbinafine and itraconazole) have previously been used for the treatment of human pythiosis. However, patients with incomplete surgical resection had almost 100% mortality. A novel therapeutic approach and reliable biomarkers are needed to improve patient outcomes.

There are several studies demonstrating excellent in vitro activity of antibacterial agents, especially macrolides, tetracyclines, and oxazolidinone against P. insidiosum. There are also evidences of synergy among antibacterial classes such as tetracyclines and macrolides. In 2019, Susaengrat, et al. reported successful treatment of two patients, who had inoperable intra-abdominal vascular pythiosis, with adjunctive antibacterial agents as salvage therapy. The medications included itraconazole in combination with doxycycline and azithromycin or clarithromycin. This case report also confirmed the result of a previous study by Worasilchai, et al. (2018) that serum 1,3-beta-D-glucan (BDG) is useful for monitoring disease activity. The ongoing multicenter prospective study is conducted to evaluate the use of antibacterial agents (azithromycin and doxycycline) with itraconazole and surgery in vascular pythiosis and to evaluate the alternative markers such as erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP). Torvorapanit, et al. (2021) reported preliminary results of 10 patients, which demonstrated favorable outcomes. It was shown that 2/4 patients with the residual disease could successfully be treated with mediations. ESR and CRP declined over time after treatment and Spearman's correlation between ESR and BDG was 0.65, and between CRP and BDG was 0.6. The study aims to recruit 50 patients, which should attest the usefulness of antibacterial agents and these markers in patients with vascular pythiosis.
P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI)
Authors: Prattes Juergen , King Thomas , Azie Nkechi , Angulo David 
Published: September 2022

Abstract

Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM

Background
There are limited oral treatment options for patients with high-mortality fungal infections such as candidemia or invasive candidiasis who fail currently available antifungals or have an infection caused by resistant organisms. Ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor with activity against Candida species, including azole- and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of ibrexafungerp (FURI; NCT03059992) is ongoing for the treatment of patients intolerant of, or with invasive fungal disease refractory to, standard antifungal therapy. We present an interim analysis of all-cause mortality within 30 days post-treatment from the FURI study by fungal disease type for patients with candidemia or invasive candidiasis, who completed therapy up until October 2021.

Methods
FURI patients are eligible for enrolment if they have proven or probable: severe mucocutaneous candidiasis or invasive candidiasis, or candidemia, with documented evidence of failure, intolerance, or toxicity related to a currently approved standard-of-care antifungal treatment; or patients who cannot receive approved oral antifungal options (eg, due to susceptibility), and continued IV antifungal therapy is clinically undesirable or unfeasible. Patients were followed through 30 days post-treatment for all-cause mortality.

Results
Out of the 113 patients who completed therapy in the FURI study through October 2021, 56 (50%) had invasive candidiasis or candidemia and were treated with ibrexafungerp. The most common infections in this group were candidemia (15/56, 26.8%), intra-abdominal infection (13/56, 23.2%), and bone infection (10/56, 17.9%).
Overall survival within 30 days post-treatment in this group of 56 patients was 94.6%. Of the 56 patients with candidemia or invasive candidiasis, three (5.3%) died within 30 days after completion of treatment with ibrexafungerp, a fourth died at 31 days, a fifth died at 50 days, and a sixth died at 56 days. The mean age of the expired patients was 56 years. All 4 patients had candidemia (3 with C. parapsilosis and 1 with C. albicans), and 2 had intra-abdominal candidiasis, (both with C. glabrata). The average time on therapy with ibrexafungerp was 15.7 days. The mean time to death post-treatment for these patients was 27 days (median, 21 days). In five cases, the deaths were due to causes other than the underlying fungal disease. For the other case, the cause of death was not disclosed.

Conclusions
Analysis of all-cause mortality in these patients from the FURI study indicates that oral ibrexafungerp provides a favorable therapeutic response in patients with challenging fungal diseases and limited treatment options.
P062 Identification of Octenidine (dihydrochloride) inhibiting fungal filamentation by the repurposing approach
Authors: Fang Ting , Ji Zhe , Lu Hui , Jiang Yuanying 
Published: September 2022

Abstract

Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM

Objectives
Hyphal formation is an important virulence factor of opportunistic pathogenic fungi and plays a vital role in invasive fungal infections. Therefore, hyphae can act as a specific target against invasive fungal infections and it is a new attempt to focus on identification of compounds inhibiting hyphal growth. Amphotericin B has potent inhibitory effect on the growth of hyphae, but its high toxicity limits its clinical use. To address this question, we performed a high-throughput screen of an FDA-approved compound library (HY-L022, MCE®) to identify compounds with mycelial inhibitory function.

Methods
We performed a high-throughput screen of an FDA-approved compounds library to identify potentially novel compounds for inhibiting hyphal growth and used amphotericin B (1.56 μm) as a positive control drug. The screening schematic is shown in Figure 1a. Firstly, we investigated the mycelial inhibitory activity of each compound at 100 μm in RPMI 1640 medium with Candida albicans SN152 strain. Secondly, micro checkboard dilution method was applied to determine the minimum hyphae-inhibiting concentration of compounds. The compound being included in the next round could inhibit the hyphal formation when its concentration was ≤12.5 μm. Lastly, we expanded medium to YPD containing 10% FBS, YPD containing 5 mm N-acetylglucosamine (GlcNAc), and Spider medium. The final Candidate compound was determined due to its minimum hyphae-inhibiting concentration was ≤3.125 μm in four mediums.

Results
We screened a library of FDA-approved compound and identified 117 Candidate compounds that inhibit hyphal growth (≤100 μm). We excluded 14 compounds with known antifungal activity, and finally 103 compounds were included in the next step of mycelial inhibitory activity screening (Fig. 1a). We further identified that 14 of 103 Candidate compounds (red square) could significantly inhibit the growth of mycelium at a concentration not higher than 12.5 μm in RPMI 1640 medium (Fig. 1b). We then expanded the types of media that induce mycelial growth (such as YPD medium with 10% FBS, YPD medium with 5 mm GlcNAc, and Spider medium) and used amphotericin B (1.56 μm) as a positive control drug and found that Octenidine (dihydrochloride) still has a significant inhibitory effect on mycelial growth in various mycelial induction media when it is as low as 3.125 μm (Figs. 2a and b).

Conclusion
Our study demonstrates that Octenidine (dihydrochloride) has a potent hyphal inhibitory activity and is helpful to open the way for the development of new antifungal therapeutics targeting filamentous formation.
P080 Comparison of efficacy of innovator molecule of itraconazole with generic forms of itraconazole in treatment naïve subjects with chronic pulmonary aspergillosis
Authors: Sehgal Inderpaul , Vinay Keshavamurth , Agarwal Ritesh , Rudramurth Shivaprakash 
Published: September 2022

Abstract

Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM

Objective
Itraconazole capsule has a variable and unpredictable bioavailability. Whether generic brands of itraconazole are as effective as the innovator molecule in the treatment of subjects with chronic pulmonary aspergillosis (CPA) is unclear. We compared the proportion of subjects who achieved therapeutic drug levels with the generic and the innovator itraconazole at 2 weeks after treatment initiation.

Methods
In this retrospective study, we compared the proportion of subjects with CPA achieving therapeutic drug levels (≥ 0.5 mg/l) with the generic and the innovator itraconazole at 2 weeks after treatment initiation. We performed a multivariate logistic regression analysis to ascertain if the trough itraconazole levels affected the treatment outcomes. We also performed morphometric analysis of different brands of itraconazole by video dermoscopy.

Results
A total of 193 [generic brands (n = 94) and innovator itraconazole (n = 99)] subjects of CPA were enrolled. The median (IQR) age of the study population [54% (105/194) men] was 42 (32-55) years. The proportion of subjects who achieved therapeutic trough itraconazole levels was significantly (P &lt;.0001) higher with the innovator than the generic brands [72/99 (73%) vs. 27/94 (29%)]. The median trough itraconazole level at 2-weeks was also higher with the innovator brand than the generic brands [0.8 (0.5-1.6) vs. 0 (0.0.5) mg/l]. The average trough itraconazole levels and the trough itraconazole levels &gt;1 mg/l independently predicted favorable treatment response after adjusting for age, gender, and CPA severity. The generic brands had a variable number, size, and a larger pellet size on the morphometric analysis. Two brands had dummy particles.

Conclusion
Significantly higher proportion of subjects achieved therapeutic drug levels with the innovator brand of itraconazole than the generic brands. Importantly, the serum itraconazole levels independently predicted a favorable response to treatment in CPA.
P087 A clinicomycological study of dermatophyte infection including antifungal susceptibility testing in patients attending a tertiary care hospital in north-western state of rajasthan
Authors: Charan Manisha , Rastogi Vijyalatha , Verma Pushpanjali , Lakhawat Rajendra Singh , Chaturvedi Parul , Jhorawat Bhawna , Mehta Mahesh 
Published: September 2022

Abstract

Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM

Objectives
Treatment-resistant ermatophytosis caused by Trichophyton rubrum (T. rubrum) or Trichophyton mentagrophytes (T. mentagrophytes)/Trichophyton indotineae have recently emerged as a global public health issue. This phenomenon is spreading, and is particularly important in endemic areas such as India. However, due to lack of focused studies on dermatophyte prevalence, there is paucity of such data from Rajasthan. Hence, for better understanding of the prevalence, antifungal susceptibility, and resistance pattern to enable best empiric treatment the present study was done.

Materials & Methods
A total of 100 patients attending Dermatology and Venereology outpatient department during the period of December 2019-October 2020 were enrolled under this prospective study. Samples were subjected to KOH, culture examination, and identified by standard techniques at the mycology section of department of microbiology. Antifungal susceptibility testing was performed by Microbroth dilution as per CLSI guidelines (M38-A2) with the following drug concentration ranges—amphotericin B 0.0313-16 μg/ml; flucytosine 0.125-64 μg/ml, ketoconazole 0.0313-16 μg/ml. Itraconazole and voriconazole 0.0078-4 μg/ml, fluconazole 0.0625-32 μg/ml, caspofungin 0.0313-16 μg/ml and terbinafine 0.0156-8 μg/ml.

Results
Among 100 clinical samples tested, culture positivity was found to be 63%, including dermatophytes (76.1%), non-dermatophytes molds (19.04%), and yeasts (∼ 4%). Among dermatophytes, T. mentagrophyte was the predominant isolate (33.3%) followed by T. rubrum (29.1%). Most common clinical type was tinea cruris (53%) followed by tinea corporis (23%). Itraconazole and voriconazole were found to be most effective at MIC range of 0.0078-4 μg/ml for T. mentagrophyte and at 0.0078-1 μg/ml for T. rubrum, mostly corroborating with clinical outcome. Itraconazole resistance was highest (57%) in T. rubrum, whereas terbinafine resistance (&gt;0.2 μg/ml) was seen in ∼ 31-37% of these two major species.

Conclusion
It is important for clinicians to emphasize upon microbiological diagnosis of dermatophytosis as these infections have many mimics, highlighting the need of confirmation by culture. High prevalence of terbinafine resistance in both T. mentagrophyte and T. rubrum and itraconazole resistance in T. rubrum is of concern and highlights the need to routinely perform antifungal drug susceptibility testing as a necessary adjunct to treatment and for surveillance.
P089 Candidemia: prevalence, species characterization ,and the antibiotic susceptibility profile from a tertiary care hospital in north india
Authors: William Ashish , Kaur Ravinder , Rawat Deepti , Kumar Pradeep 
Published: September 2022

Abstract

Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM

Objectives
The aim of this study was to characterize the Candida spp. isolated from blood cultures and determine the antifungal susceptibility pattern of the Candida species prevalent in a tertiary care hospital in North India.

Methods
This retrospective study was conducted in Department of Microbiology of a tertiary care hospital in North India from April 2020 to March 2022. All blood cultures received in the department during this period were included in the study. Candida species isolated were identified and antifungal susceptibility testing was performed by VITEK as per standard protocol, The susceptibility pattern of 50 isolates was also performed by the broth microdilution method as per Clinical and Laboratory Standards Institute guidelines (CLSI) and the results were compared with VITEK results.

Results
Out of 21 804 blood cultures received during this period, 177 grew Candida species. Therefore, the overall prevalence of Candida species was 0.81% in our study. The incidence of bloodstream infection caused by non-albicans Candida species (80%) was higher than C. albicans (20%). Among NAC species, C. tropicalis (45%) was the most common, followed by C. pelliculosa (15%).
Candidemia was predominantly observed in ICU patients. Resistance was seen in 14.1% isolates to voriconazole and fluconazole, 4.2% to flucytosine and 3.9% to caspofungin and amphotericin-B. No resistance was seen to micafungin. A total of 15% of the isolates were resistant to more than one drug.

Conclusion
There was a predominance of non-albicans Candida over C. albicans. Maximum resistance was seen to voriconazole followed by fluconazole. Continuous surveillance is necessary to follow trends and monitor changes in epidemiological and resistance patterns in different geographical regions, especially in critically ill patients.